What Happened
The FDA has expanded the label for tirzepatide (Mounjaro) to include reducing the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack and non-fatal stroke — in adults with type 2 diabetes who are at high cardiovascular risk. It is the first dual GIP/GLP-1 receptor agonist with a cardiovascular claim; the drug was already approved for blood sugar in adults and children 10 and older.
The decision rests on SURPASS-CVOT (NCT04255433), an event-driven, randomized, double-blind trial that enrolled more than 13,000 adults with type 2 diabetes and established atherosclerotic cardiovascular disease at 640 sites across 30 countries, with a median follow-up of 210.1 weeks — roughly four years. Unusually, the comparator was not placebo but dulaglutide (Trulicity), an older GLP-1 receptor agonist that already carries its own cardiovascular indication.
The design makes the result easy to overstate. Mounjaro was non-inferior to dulaglutide: an 8% lower rate of the three-point composite, hazard ratio 0.92 with a 95.3% confidence interval of 0.83 to 1.01. The interval touches 1.00, and the manufacturer states that superiority was not established. The claim rests on equivalence to an existing standard of care, not on beating placebo.
Who Is Affected
- Patients with type 2 diabetes and established heart disease gain a second incretin option tested for cardiovascular non-inferiority in a dedicated outcomes trial, rather than having it inferred from glucose lowering.
- Prescribers have a label basis to choose tirzepatide partly on cardiovascular grounds, though the trial does not show it is better than dulaglutide there.
- Compounding pharmacies and gray-market sellers are affected indirectly. Tirzepatide is not on the FDA shortage list, so routine compounding of the finished drug is not permitted under section 503A — and sellers of "research-use" vials sit outside that framework entirely.
- Payers acquire a formal risk-reduction rationale, which typically tightens prior authorization.
Timeline
- 2026 — SURPASS-CVOT reports a median 210.1 weeks of follow-up in more than 13,000 participants.
- August 28, 2026 — FDA approves the cardiovascular risk-reduction indication for Mounjaro.
- October 30, 2026 — HHS publishes a separate draft enforcement discretion policy covering six compounded peptides (BPC-157, TB-500, epitalon, KPV, MOTS-c, semax). It does not touch GLP-1 or GIP drugs.
- November 1, 2026 — Clinicians and payers begin folding the new label language into formularies.
What This Means for Researchers
- Read the endpoint, not the adjective. Here it means non-inferiority to an active comparator over four years in a secondary-prevention population.
- The trial cannot isolate GIP from GLP-1. With no placebo arm and no GLP-1-only arm, it says nothing about how much of the effect comes from added GIP receptor activity.
- Outcomes assume a validated product. The claim attaches to a specific manufactured molecule, not to a name on a vial; identity, purity and concentration are prerequisites.
- Class-wide inference is unsafe. These results do not transfer to unapproved analogues or research-use peptides sold under similar names.
How to Verify Your Peptides
- Read how independent testing works and what a legitimate certificate of analysis must contain.
- See why HPLC and LC-MS answer different questions.
- Check what a lab actually reports: identity, purity and fill weight.
- Compare sellers that publish third-party results in our vendor directory.
Safe Alternatives
For anyone weighing incretin therapy, the approved options are the reference point: see our profiles of tirzepatide and semaglutide, then read the head-to-head semaglutide vs tirzepatide comparison. Browse the wider peptide library for what has been tested in humans.
Sources
Regulatory announcements; company statements; trial registry records; industry reports.